位置:首页 > 产品库 > SBI-115
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
SBI-115
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
SBI-115图片
CAS NO:882366-16-7
规格:≥98%
包装与价格:
包装价格(元)
5mg询价
10mg询价
25mg询价
50mg询价
100mg询价
250mg询价
500mg询价

理化性质和储存条件


Name: SBI-115
CAS#: 882366-16-7
Chemical Formula: C14H13ClN2O4S
Exact Mass: 340.0285
Molecular Weight: 340.778
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Technical InformationSynonym: SBI115; SBI 115; SBI-115
Chemical Name: 4-Pyrimidinecarboxylic acid, 5-chloro-2-(ethylsulfonyl)-, 3-methylphenyl ester
InChi Key: IJPXOPBVXVPPEW-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H13ClN2O4S/c1-3-22(19,20)14-16-8-11(15)12(17-14)13(18)21-10-6-4-5-9(2)7-10/h4-8H,3H2,1-2H3
SMILES Code: O=C(C1=NC(S(=O)(CC)=O)=NC=C1Cl)OC2=CC=CC(C)=C2
实验参考方法
In VitroSBI-115 (100 and 200 μM, 24 hours) inhibits proliferation triggered by pre-treatment of cystic cholangiocytes with Taurolithocholic acid (TLCA) in shRNA-transfected ADPKD cholangiocytes[1]. Cell Proliferation Assay[1] Cell Line: shRNA-transfected ADPKD cholangiocytes Concentration: 100 and 200 μM Incubation Time: 24 hours Result: Inhibited proliferation (by 32-48%) triggered by pre-treatment of cystic cholangiocytes with TLCA.
ReferenceHepatology. 2017 Oct; 66(4):1197-1218.
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024